



Assistant Professor of Medicine  
La Sapienza, University of Rome  
[@sapienzaroma](#)

**PROF. ALESSIO MOLFINO**

Alessio Molfino is currently Assistant Professor of Medicine, at Sapienza University of Rome, Italy. He received his M.D. cum laude in 2003 at Sapienza University of Rome, Italy, and he concluded cum laude in 2008 his residency/fellowship in Internal Medicine. In 2012 he received his Ph.D. in Clinical and Preventive Nutrition at University of Rome “Tor Vergata”. During the years 2010-2015 he was Research Associate at University of California, Davis, U.S.A. His principal fields of research are protein-energy malnutrition, metabolism, anorexia and cachexia associated with chronic diseases, such as cancer and hemodialysis. He received several awards from national and international societies of Internal Medicine and from a prestigious international Foundation devoted to cancer research.



Head, Quality of Life  
Department  
EORTC  
[@eortc](#)

**DR. ANDREW BOTTOMLEY**

Dr Bottomley’s passion for more than the last two decades has been to understand the consequences of cancer and its treatment on patients HRQOL and psychosocial functioning. For over 18 years he has been the Head of the European Organisation for Treatment of Cancer (EORTC) Quality of Life Department, based in Brussels Belgium. This post involves working at an international level, developing HRQOL outcomes research policies and instrument methodology in the cancer clinical trials arena. He has published 160 peer-reviewed papers in major cancer journals, 25 book chapters and co-authored 200 peer-reviewed abstracts for international conferences such as ASCO and ECCO. He serves on ten editorial Boards. Dr Bottomley has been the editor for 2 major journals. He has served for six years on the ethical committee of the WHO International Agency for Research in Cancer, in Lyon in France and serves as a scientific advisor the European Commission for the 7th Framework program as well as an ethical advisor for the European Research Council. He is a founding member of the Cochrane Patient- Reported Outcomes Methods Group and has been an Executive member of the EORTC Quality of Life Group for over 18 years.



Medical Director, Evaluative  
Epidemiology Unit  
Istituto Nazionale dei Tumori  
[@isttumori](#)

**DR. ANNALISA TRAMA**

Dr. Annalisa Trama is a dynamic and enthusiastic researcher with an international experience in descriptive and evaluative epidemiological multicentres studies. Since 2009 she works as medical director at the Evaluative Epidemiology Unit of the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, Italy where she is involved with national and international projects and initiatives on rare cancers, including the Joint Action on Rare Cancers and the EU project RARECAREnet. Besides her experience on cancer, Dr. Trama has also worked on HIV and AIDS. Furthermore, she is proficient in resource mobilisation, project management and multistakeholders initiatives.



Director General  
EORTC  
[@eortc](#)

**DR. DENIS LACOMBE**

Dr Lacombe rose to the position of Director EORTC Headquarters in 2010, and in April 2015 was appointed EORTC Director General. In his current position, Denis Lacombe is now involved in the coordination and administration of all EORTC activities in order to promote the EORTC as a major European organization in Cancer Clinical and Translational Research and is responsible for the organization of scientific activities, public relations and medium-term strategies as defined by the EORTC Board as well as for internal and external communications.



Head of EU Affairs  
European Cancer  
Patient Coalition  
[@francescoflo](#)  
[@cancereu](#)

MR. FRANCESCO FLORINDI

Francesco joined ECPC in March 2014 as Public Affairs Coordinator. He obtained a cum laude Master in International Relations and Diplomacy from the University of Trieste-Gorizia with a thesis on EU enlargement. In Brussels, Francesco worked for regional representatives, NGOs, research centres and the European Commission (Joint Research Centre). His experience working on cancer dates back to 2013, when he joined ECCO and SIOPE Public Affairs team. This experience raised his awareness of the challenges faced by patients. Hence, he quickly moved to the side of patients, putting his policy and public affairs skills to ECPC’s service, helping the ECPC Board to produce a new policy strategy (“Europe of Disparities in Cancer”) and to deliver several high profile projects.

Francesco is a fellow Young Gasteiner and a Member of the European Health Parliament.



Director of Special Projects  
EORTC  
[@eortc](#)

MS. FRANÇOISE MEUNIER

Françoise Meunier served as EORTC Director General from 1991 through 2015 and oversaw the growth of the EORTC into an international world class cancer clinical research infrastructure. Upon stepping down as Director General in 2015, Françoise remains active as EORTC Director Special Projects where she is a driving force behind activities such as EORTC cancer survivorship initiatives. She also lends her valuable experience to fundraising projects and sits on the board of the EORTC Cancer Research Fund.



PREFER Deputy Coordinator  
University of Leuven  
[@IMI\\_JU](#)

PROF. ISABELLE HUYS

Prof. dr. Isabelle Huys is pharmacist by training and with PhD in pharmaceutical sciences and further specialisation in the regulations around medicinal product development at KU Leuven. Her research focusses on access to medicines and therapies. The research program studies diverse legal and regulatory aspects along the continuum of a medicinal product life cycle, from medicinal product discovery, development, approval, reimbursement and market adoption. The research program focuses on all types of medicinal products (small molecules, biologicals, advanced therapy medicinal products (ATMPs)). Topics include biobanking and access to (human) biological samples and data, the use of real-world data in medicinal product development, repurposing of medicines for cancer indications, patient preferences in medicinal product development, precision medicine and companion diagnostics, off-patent strategies of biological products and market access of biosimilar and drug shortages. Isabelle Huys supervises PhD projects in this research program and publishes the research in diverse journals.



Dean of Education, Faculty of  
Medicine, Health and Life  
Sciences  
Queen’s University Belfast  
[@QueensUBelfast](#)

PROF. MARK LAWLER

Mark is Chair in Translational Cancer Genomics in the Centre for Cancer Research and Cell Biology and Dean of Education for the Faculty of Medicine, Health and Life Sciences at Queen’s University Belfast (QUB). He has published over 170 papers in high impact international journals and received a number of prestigious national and international awards for his research. Mark recently issued a Call to Action in the New England Journal of Medicine highlighting the need for global sharing of genomic, epidemiological and clinical data for the benefit of patients. He presented his data sharing blueprint and how it can contribute to global precision health during the United Nations (UN) General Assembly at the UN Building in New York in late 2016. He is also active in citizen driven health. As Vice President of the European Cancer Concord (ECC), an equal partnership between patients and healthcare professionals, he was the architect of the European Cancer Patient’s Bill of

Rights, launched by ECPC on World Cancer Day 2014 in the European Parliament in Strasbourg. Mark interacted closely with ECPC on the launch of the Bill of Rights and continues to work with ECPC on their initiatives including the Europe of Disparities in Cancer. Recently, Mark was invited to join the newly established Scientific Committee of ECPC. Mark was also recently appointed to the Board of the European Alliance for Personalised Medicine (EAPM) and is hosting the EAPM Congress “Personalising Your Health: A Global Imperative!” which is an EU Presidency event that will take place in Belfast from 27th – 30th November 2017.



*Professor Internal Medicine  
La Sapienza, University of Rome  
@sapienzaroma*

**PROF. MAURIZIO MUSCARITOLI**

Maurizio Muscaritoli is Full Professor of Internal Medicine and Director of the Unit of Internal Medicine and Clinical Nutrition at the Department of Clinical Medicine, Sapienza University of Rome, Italy. His main research interest are the nutritional and metabolic changes in chronic diseases, including cancer. In particular, the most recent research activity has focussed on the molecular mechanisms responsible for muscle wasting in cancer cachexia, in both experimental models and in human cancer. He is a member of ESPEN, the European Society of Clinical Nutrition and Metabolism, where he is chairing a Special Interest Group on Cachexia-Anorexia in Chronic Diseases and Coordinator of the Nutrition Education Study Group (NESG). He is actively collaborating with the Italian Associations of Cancer Patients (AIMaC) and with the Italian Federation of Cancer Patients Organisations (FAVO), for which he has created leaflets and booklets for patients addressing the issues of weight loss and nutrition during cancer. He has developed the concept of the “Parallel Pathway” to optimize the metabolic and nutritional support of cancer patients. From 2006 to 2009 he was the Chairman of SINPE, the Italian Society of Artificial Nutrition and Metabolism. He is the founder and Chairman of SINuC, The Italian Society of Clinical Nutrition and Metabolism. He is co-author of several book chapters and scientific papers in peer-reviewed journals. He is Chief Editor of Frontiers in Clinical Nutrition. Along with his group and on behalf of the Society for Sarcopenia, Cachexia and Wasting Diseases (SCWD) he will organize the next Cachexia Conference to be held in Rome in December 2017.



*Department of Psychosocial  
Research, Division of  
Psychosocial Research &  
Epidemiology  
Netherlands Cancer Institute  
@NKI\_nl*

**PROF. NEIL K. AARONSON**

Neil Aaronson, PhD received his undergraduate and graduate training at the University of California, Los Angeles. His graduate training was in clinical psychology, medical sociology and psychiatric epidemiology. He is currently a senior staff scientist in the Division of Psychosocial Research and Epidemiology at the Netherlands Cancer Institute, and Emeritus Professor in the Department of Clinical Psychology at the University of Amsterdam. He has served as the chairman of the European Organization for Research and Treatment of Cancer Quality of Life Group, President of the International Society for Quality of Life Research (ISOQOL), and as a member of the board of directors of the International Psycho-Oncology Society (IPOS). He received the President’s Award from ISOQOL and the Bernard Fox Memorial Award from IPOS, and is a fellow of the European Academy of Cancer Sciences. Dr. Aaronson served as the editor-in-chief of the journal Quality of Life Research, and is currently an associate editor of the Journal of the National Cancer Institute and the Journal of Cancer Survivorship, and is a member of the editorial boards of the Journal of Clinical Oncology and the Journal of Patient-Reported Outcomes. Dr. Aaronson's primary research interests are in the development of methods for assessing health-related quality of life and other patient-reported outcomes, the integration of PRO assessments into clinical trials and clinical practice, and the development and testing of behavioral and psychosocial interventions in oncology. He is the author of more than 350 articles in the peer-reviewed, professional literature.



Executive Board member  
ESMO  
[@myESMO](#)

**DR. STEFAN RAUH**

Dr Stefan Rauh currently works as haemato-oncologist at the Centre Hospitalier Emile Mayrisch, Esch, LU with mainly clinical and some teaching and clinical research activities.

He is member of national Oncology societies, ASH, ASCO, HVO, UEMS and member of the UEMS ETR working group in Medical Oncology.

He has been involved in ESMO, as qualified member since 1999, National Representative 2006 - 2014, Executive Board member 2015 and 2016, Public Policy Working Group extended member, Practicing Oncologists' Committee chair since 2015, Quality Task Force chair 2015-2017; member since 2017, and Educational Steering Committee member since 2017.



Coordinator  
Joint Action on Cancer Control  
(CanCon)  
[@TitAlbreht](#)  
[@EU\\_CanCon](#)

**PROF. TIT ALBREHT**

Dr. Tit Albreht, M.D. (1961), Slovenian, Ph.D. in Health Services Research at the University of Amsterdam, Head of the Centre for Health Care at the National Institute of Public Health of Slovenia. A senior researcher in the field of health services research, health policy and health systems research, member of the Scientific Committee of EUPHA, president of the Slovenian Preventive Medicine Society, member of the Health Council of the Ministry of Health of Slovenia. He acts as a reviewer of several scientific journals and of projects submitted for financing to the European Commission.

From 2011 to 2014 he was a work package leader of the Work Package in the Joint Action EPAAC – European Partnership for Action Against Cancer. This process resulted in the European Guide on National Cancer Control Programmes. Since 2014, he is the co-ordinator of the Joint Action Cancon (Cancer Control), an EU co-financed project dedicated to informing the development of cancer policies at the EU and Member State levels. He is an Associate Professor of Public Health at the Medical Faculty of Ljubljana, Slovenia and teaching public health and epidemiology at the Medical Faculty of Maribor and at the University of Primorska.



Executive Board member  
Netherlands Cancer Institute  
[@wimvanharten](#)

**PROF. WIM VAN HARTEN**

Wim H. van Harten spent 5 years in Cameroon after his graduation as M.D. and specialization in tropical medicine. On returning from Africa he focused on public health and health administration. He obtained a degree in community medicine/public health while working as Chief Medical Advisor of a major health insurance company (1986-1992). From 1992 to 2001, he worked at the rehabilitation hospital “Het Roessingh” in Enschede, as General Director, he completed his Ph.D. on quality management in health care (1997) and started a research group. In June 2001, he became Member of the Executive Board of the Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NKI-AVL) in Amsterdam, The Netherlands, being in charge of Organization & Management. The NKI is the only designated Comprehensive Cancer centre in the Netherlands with an annual expenditure of over € 300 million. From 2005 onwards he was acting as Research Group leader at the Division of Psychosocial Research and Epidemiology at the NKI. Since 2001 he is part-time professor on “Quality Management and Health Care Technology” at the department of Health Technology and Services Research of the School of Management and Governance at the University of Twente, the Netherlands. He supervised over 10 Ph.D graduates and presently his group consists of 2 postdocs and 5 PhD students in the NKI and 2 in other universities. He published over 100 peer reviewed papers on Health Technology Assessment, process improvement in oncology and survivorship and e-health. On 2006 he was elected Member of the Board of the Organization of European Cancer Institutes (OECI) and in 201-2014 he served as President of the OECI. From 2008 – 2014 he acted as Board member of the Netherlands Hospital Association. In December 2015 he started as CEO of Rijnstate (general) Hospital in Arnhem.